Rozlytrek (Entrectinib)

Save over 60% on Rozlytek from Europe.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

All European Rozlytrek is manufactured at: Roche Pharma AG Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany

Information about Rozlytrek (Entrectinib)

Rozlytrek (generic name: Entrectinib) is a targeted therapy used to treat certain types of cancer. It is a tyrosine kinase inhibitor that works by blocking specific proteins, known as tyrosine kinases, which play a role in the growth and spread of cancer cells. Entrectinib is particularly effective for cancers driven by specific genetic mutations, such as those involving the NTRK (neurotrophic receptor tyrosine kinase) gene fusion, ROS1, and ALK. It is designed to interfere with the abnormal signaling pathways in these cancers to slow their progression.

Product Highlights

• It is effective in treating cancers like non-small cell lung cancer (NSCLC), colon cancer, or soft tissue sarcoma that involve NTRK gene fusions, regardless of the tumor's origin.
• Rozlytrek is approved for patients with ROS1-positive NSCLC who have not responded to previous therapies or in the metastatic setting.
• Rozlytrek is also used for cancers that have the ALK gene rearrangement, which is common in some types of lung cancer.
• Rozlytrek can be used in other cancers with these genetic mutations that have spread or are resistant to standard treatments.

Key Ingredient

• Entrectinib

Key Benefits

• Rozlytrek is highly effective in treating cancers with specific genetic alterations, leading to better outcomes for patients with rare mutations.
• It is approved for a broad range of cancers across various body sites that have NTRK, ROS1, or ALK mutations, offering a treatment option for patients who may not respond to traditional chemotherapy or radiation.
• As a targeted therapy, Rozlytrek may have fewer side effects compared to chemotherapy because it specifically targets cancer cells with the relevant genetic mutations.
• Studies show that Rozlytrek can result in durable responses in patients, particularly in those with ROS1-positive NSCLC or NTRK gene fusions.

Direction of Use

• Rozlytrek is taken as an oral capsule, usually once a day.
• The standard dose is 600 mg once daily. The dosage may vary based on patient response or other factors, so it's important to follow the prescribing healthcare provider's instructions.
• Rozlytrek can be taken with or without food, and should be swallowed whole, not crushed or chewed.

Safety Concerns

• Rozlytrek may cause heart problems, including QT prolongation, which can lead to abnormal heart rhythms. Frequent monitoring of heart function may be necessary. 
• It can affect liver function, leading to liver enzyme elevation. Liver function tests should be conducted routinely throughout the treatment. 
• Common side effects include fatigue, dizziness, and headaches.
• Nausea, diarrhea, and constipation may occur, especially at the beginning of treatment.
• Rozlytrek can increase the risk of bleeding due to its effect on platelet aggregation. Patients may experience bruising or bleeding more easily.

Avoid Rozlytrek (Entrectinib) If

• Do not use Rozlytrek if you are allergic to entrectinib or any of the excipients in the formulation.
• Rozlytrek should be avoided in patients with severe liver problems, as it may exacerbate liver toxicity or cause further liver damage.
• Rozlytrek is not recommended during pregnancy, as it may harm the developing fetus. Women who are pregnant or breastfeeding should consult their healthcare provider before using Rozlytrek.
• If you have a history of QT prolongation or other heart problems, Rozlytrek may not be suitable due to its potential to worsen these conditions.
• Rozlytrek may interact with certain medications that affect liver enzymes, especially CYP3A4 inhibitors or inducers. These interactions can increase or decrease the effectiveness of Rozlytrek and may require dose adjustments.